Application of AI Technology for the Diagnosis and Treatment of Geriatric Diseases

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Mar 3, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring how artificial intelligence (AI) can help diagnose and treat conditions that affect older adults, such as Parkinson's disease, Alzheimer's disease, and other nervous system disorders. Researchers will look at various characteristics, including how people write, walk, speak, and move their eyes, as well as biological samples like blood and saliva. They aim to gather information from around 400 participants, including patients with these conditions and healthy individuals of different ages, to better understand how these diseases affect the body and brain.

To be eligible for the study, participants must be diagnosed with Parkinson's or Alzheimer's disease or have other neurodegenerative diseases. Healthy volunteers, both elderly and younger than 60, can also join if they meet certain criteria. Participants can expect to undergo various tests to collect the necessary data, and they will be contributing to important research that could improve how we understand and treat these diseases in the future. It's essential to know that the study is currently recruiting, and participants will need to provide informed consent before joining.

Gender

ALL

Eligibility criteria

• • 1. Inclusion Criteria 1.1 A total of 100 patients with primary Parkinson's disease were enrolled. The inclusion criteria were as follows: patients with primary Parkinson's disease, based on the 2015 MDS diagnostic criteria for Parkinson's disease. Disorder (MMSE score \< 24); (3) those with severe mental illness who are difficult to cooperate.
• • 1.2 A total of 100 patients with Alzheimer's disease were enrolled. The inclusion criteria were as follows: patients with Alzheimer's disease, based on the IWG-2 clinical diagnostic criteria.
• • 1.3 Neurodegenerative diseases (non-PD and non-AD) group (n = 100) : meeting the diagnostic criteria of the corresponding diseases.
• • 1.4 Eighty healthy elderly controls were included. The inclusion criteria were as follows: ① voluntarily participated in this study and signed the informed consent; ② Age and gender were matched with the case group.
• • 1.5 80 young healthy controls, inclusion criteria: ① voluntarily participated in this study and signed the informed consent; ② Gender was matched with the case group, and the age was less than 60 years old.
• • 2. Exclusion Criteria 2.1 A total of 100 patients with PD were enrolled. Exclusion criteria: ① patients with other central nervous system diseases, such as cerebrovascular diseases, brain trauma, inflammatory diseases of the central system, intracranial tumors and after neurosurgery; ② patients with various types of cognitive impairment (MMSE score \< 24); (3) those with severe mental illness who are difficult to cooperate.
• • 2.2 A total of 100 patients with Alzheimer's disease were enrolled. The exclusion criteria were: ① patients with other central nervous system diseases, such as cerebrovascular diseases, brain trauma, central system inflammatory diseases, intracranial tumors and after neurosurgery; ② patients with severe mental illness who are difficult to cooperate.
• • 2.3 Neurodegenerative diseases (non-PD non-AD) group (n = 100), exclusion criteria: ① patients with other central nervous system diseases, such as cerebrovascular diseases, brain trauma, central system inflammatory diseases, intracranial tumors and after neurosurgery; ② patients with severe mental illness who are difficult to cooperate.
• • 2.4 Eighty healthy elderly controls were included. The exclusion criteria were as follows: ① History of chronic diseases related to the study subjects, such as cerebrovascular diseases, brain trauma, inflammatory diseases of the central system, intracranial tumors and neurosurgery; ② patients with various types of cognitive impairment (MMSE score \< 24); ③ Poor compliance.
• • 2.5 80 young healthy controls, exclusion criteria: ① history of chronic diseases related to the study subjects, such as cerebrovascular diseases, brain trauma, inflammatory diseases of the central system, intracranial tumors and neurosurgical surgery; ② patients with various types of cognitive impairment (MMSE score \< 24); ③ Poor compliance.